2-溴-n-十六基乙酰胺 | 1138445-61-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-溴-n-十六基乙酰胺
• 中文别名: 2-溴-N-十六烷乙酰胺
• 英文名称: 2-bromo-N-hexadecylacetamide
• 英文别名: 2-bromo-N-hexadecylethanamide
• CAS: 1138445-61-0
• 化学式: C₁₈H₃₆BrNO
• 分子量: 362.394
• InChiKey: SEFRJSBFZDHSLJ-UHFFFAOYSA-N

物化性质

• 保留指数：
  2558

计算性质

• 辛醇/水分配系数(LogP)：
  8.1
• 重原子数：
  21
• 可旋转键数：
  16
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2924199090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P264,P270,P271,P280,P303+P361+P353,P304+P340,P305+P351+P338,P310,P330,P331,P363,P403+P233,P501
• 危险品运输编号：
  1759
• 危险性描述：
  H302,H314

反应信息

• 作为反应物：
  描述：

  2-溴-n-十六基乙酰胺 以 乙醇 、 氯仿 、 水 为溶剂， 反应 48.0h， 生成 N,N′-(ethane-1,2-diethanamide) bis(N,N-dimethyl-(N′-hexadecylethanamide)ammonium bromide)
  参考文献：
  名称：

  Membrane Active Small Molecules Show Selective Broad Spectrum Antibacterial Activity with No Detectable Resistance and Eradicate Biofilms

  摘要：

  Treating bacterial biofilms With conventional antibiotics is limited due to ineffectiveness of the drugs and higher propensity to develop bacterial resistance. Development of new classes of antibacterial therapeutics with alternative mechanisms of action has become imperative. Herein, we report the design, synthesis, and biological evaluations of novel membrane,active small molecules featuring two positive charges, four nonpeptidic,amide groups, and variable hydro, phobic/hydrophilic (amphiphilic) character. The biocides synthesized via a facile methodology not only displayed good antibacterial activity against wild-type bacteria but also showed high activity against various drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium (VRE), and beta-lactam-resistant Klebsiella pneumoniae. Further, these biocides not only inhibited the formation of biofilms but also disrupted the established S. aureus and E. coli biofilms. The membrane-active biocides hindered the propensity to develop bacterial resistance. Moreover; the biocides showed negligible toxicity against mammalian cells and thus bear potential to be used as therapeutic agents.

  DOI：

  10.1021/acs.jmedchem.5b00443
• 作为产物：
  描述：

  十六胺 、 溴乙酰溴 在 potassium carbonate 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 16.0h， 以99%的产率得到2-溴-n-十六基乙酰胺
  参考文献：
  名称：

  两亲性 EuDOTA-四酰胺复合物形成具有增强 CEST 敏感性的胶束

  摘要：

  报道了四种具有可变烷基链长度（C(1)、C(12)、C(14) 和 C(16)）的新型 DOTA-四酰胺配体及其各自的铕 (III) 配合物的合成和表征。三个具有长烷基链的 EuL 复合物自发形成不同大小的胶束。每种复合物的临界胶束浓度不同（C(16) 复合物低于 C(12) 复合物），而胶束尺寸随着烷基链长度的增加而增加。化学交换饱和转移 (CEST) 实验表明，所有四种 Eu(III) 配合物均表现出慢至中等的水交换动力学。正如预期的那样，由于水交换速度加快，这些复合物中的 CEST 信号随着温度的升高而降低，但有趣的是，C(14) 和 C(16) 复合物的 CEST 信号在 25°C 附近达到最大值，与交换限制的 CEST 一致。或接近室温。通过将 CEST 光谱拟合到 Bloch 方程获得的水停留寿命随着烷基碳链长度的增加而增加。通过与作为对照的单甲酰胺复合物进行比较，数据表明胶束

  DOI：

  10.1002/ejic.201101369

文献信息

• [EN] OXYTOCIN DERIVATIVES WITH IMPROVED PROPERTIES<br/>[FR] DÉRIVÉS D'OCYTOCINE AYANT DES PROPRIÉTÉS AMÉLIORÉES
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2021126990A1

  公开（公告）日：2021-06-24

  The present invention provides novel oxytocin derivative compounds that contain a fatty acid moiety that is conjugated to a modified oxytocin scaffold. The oxytocin derivative compounds of the invention are potent oxytocin agonists with substantially improved stability. Also provided in the invention are therapeutic methods of using the compounds in the treatment of various diseases, e.g., metabolic disorders such as obesity.

  本发明提供了一种新型催产素衍生物化合物，其中含有与修改后的催产素骨架共轭的脂肪酸基团。本发明的催产素衍生物化合物是有效的催产素激动剂，并具有显著改善的稳定性。本发明还提供了使用这些化合物治疗各种疾病的治疗方法，例如代谢性疾病，如肥胖症。
• Synthetic, structural mimetics of the β-hairpin flap of HIV-1 protease inhibit enzyme function
  作者：Jay Chauhan、Shen-En Chen、Katherine J. Fenstermacher、Aurash Naser-Tavakolian、Tali Reingewertz、Rosene Salmo、Christian Lee、Emori Williams、Mithun Raje、Eric Sundberg、Jeffrey J. DeStefano、Ernesto Freire、Steven Fletcher

  DOI：10.1016/j.bmc.2015.09.002

  日期：2015.11

  Small-molecule mimetics of the beta-hairpin flap of HIV-1 protease (HIV-1 PR) were designed based on a 1,4-benzodiazepine scaffold as a strategy to interfere with the flap-flap protein-protein interaction, which functions as a gated mechanism to control access to the active site. Michaelis-Menten kinetics suggested our small-molecules are competitive inhibitors, which indicates the mode of inhibition is through binding the active site or sterically blocking access to the active site and preventing flap closure, as designed. More generally, a new bioactive scaffold for HIV-1PR inhibition has been discovered, with the most potent compound inhibiting the protease with a modest K-i of 11 mu M. (C) 2015 Elsevier Ltd. All rights reserved.